Extraordinary BioMed Seminar
by Prof. Yardena Samuels . Knell Family Professorial Chair, Director, the EKARD Institute for Cancer Diagnosis Research, President Elect, European Association for Cancer Research. Department of Molecular Cell Biology. The Weizmann Institute of Science. Rehovot, Israel
Abstract:
Immunotherapy has sparked new hope for oncology in recent years, due to its remarkable ability to induce long-term tumor regression of metastatic cancer. Accumulating evidence suggest that tumor regression observed with immunotherapy are driven by targeted elimination of antigen-bearing tumor cells that are explicitly recognized by T-lymphocytes.
Our systematic analysis of melanoma tumors for HLA-presented peptides using HLA peptidomics has allowed us to identify cancer/melanoma antigens, neo-antigens, intracellular microbial antigens and aberrant peptides. Our studies reveal that the landscape of melanoma-presented HLA-peptides is highly complex. We will discuss relevant mechanisms, effects on immune recognition and therapeutic implications.
IMPORTANT: For attendees outside the PCB community you must register at least 24h before the seminar.